Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity - PubMed

Affiliations

• PMID: 12481415

Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity

Mikhail V Blagosklonny et al. Mol Cancer Ther. 2002 Sep.

Abstract

By preventing deacetylation of histones, histone deacetylase inhibitors (HDIs) transcriptionally induce p21. Here we show that the HDIs sodium butyrate (Bu), trichostatin A (TSA) and depsipeptide (FR901228) all induced p21, but only TSA and FR901228 caused mitotic arrest (in addition to arrest in G1 and G2). The ability to cause mitotic arrest correlated with the higher cytotoxicity of these compounds. Although causing mitotic arrest, TSA and FR901228 (unlike paclitaxel) did not affect tubulin polymerization. Unlike FR9012208, TSA caused acetylation of tubulin at lysine 40; both soluble tubulin and microtubules were acetylated. Whereas the induction of p21 reached a maximum by 8 h, tubulin was maximally acetylated after only 1 h of TSA treatment. Tubulin acetylation was detectable after treatment with 12-25 ng/ml TSA although acetylation plateaued at 50 ng/ml TSA, coinciding with G2-M arrest, appearance of cells with a sub-2N DNA content, poly(ADP-ribose) polymerase cleavage, and rapid cell death. We conclude that HDIs have differential effects on non-histone deacetylases and that rapid acetylation of tubulin caused by TSA is a marker of nontranscriptional effects of TSA.

Similar articles

• FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells.

  Sato N, Ohta T, Kitagawa H, Kayahara M, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Miwa K. Sato N, et al. Int J Oncol. 2004 Mar;24(3):679-85. Int J Oncol. 2004. PMID: 14767553

• FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

  Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. Nakajima H, et al. Exp Cell Res. 1998 May 25;241(1):126-33. doi: 10.1006/excr.1998.4027. Exp Cell Res. 1998. PMID: 9633520

• Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines.

  Klisovic DD, Katz SE, Effron D, Klisovic MI, Wickham J, Parthun MR, Guimond M, Marcucci G. Klisovic DD, et al. Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2390-8. doi: 10.1167/iovs.02-1052. Invest Ophthalmol Vis Sci. 2003. PMID: 12766035

• Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites.

  Sowa Y, Orita T, Hiranabe-Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T. Sowa Y, et al. Ann N Y Acad Sci. 1999;886:195-9. doi: 10.1111/j.1749-6632.1999.tb09415.x. Ann N Y Acad Sci. 1999. PMID: 10667218 Review.

• Histone deacetylase as a new target for cancer chemotherapy.

  Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S. Yoshida M, et al. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S20-6. doi: 10.1007/s002800100300. Cancer Chemother Pharmacol. 2001. PMID: 11587361 Review.

Cited by

• Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers.

  Singh BN, Zhou H, Li J, Tipton T, Wang B, Shao G, Gilbert EN, Li Q, Jiang SW. Singh BN, et al. Future Oncol. 2011 Dec;7(12):1415-28. doi: 10.2217/fon.11.124. Future Oncol. 2011. PMID: 22112317 Free PMC article. Review.

• Multiple roles of class I HDACs in proliferation, differentiation, and development.

  Reichert N, Choukrallah MA, Matthias P. Reichert N, et al. Cell Mol Life Sci. 2012 Jul;69(13):2173-87. doi: 10.1007/s00018-012-0921-9. Cell Mol Life Sci. 2012. PMID: 22286122 Free PMC article. Review.

• Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma.

  Havas AP, Rodrigues KB, Bhakta A, Demirjian JA, Hahn S, Tran J, Scavello M, Tula-Sanchez AA, Zeng Y, Schmelz M, Smith CL. Havas AP, et al. Cancer Biol Ther. 2016 Dec;17(12):1240-1252. doi: 10.1080/15384047.2016.1250046. Epub 2016 Oct 28. Cancer Biol Ther. 2016. PMID: 27791595 Free PMC article.

• Characterisation of the GRAF gene promoter and its methylation in patients with acute myeloid leukaemia and myelodysplastic syndrome.

  Bojesen SE, Ammerpohl O, Weinhäusl A, Haas OA, Mettal H, Bohle RM, Borkhardt A, Fuchs U. Bojesen SE, et al. Br J Cancer. 2006 Jan 30;94(2):323-32. doi: 10.1038/sj.bjc.6602939. Br J Cancer. 2006. PMID: 16404424 Free PMC article.

• Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets.

  Bajbouj K, Al-Ali A, Ramakrishnan RK, Saber-Ayad M, Hamid Q. Bajbouj K, et al. Int J Mol Sci. 2021 Oct 28;22(21):11701. doi: 10.3390/ijms222111701. Int J Mol Sci. 2021. PMID: 34769131 Free PMC article. Review.

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program